Payer Almanac
About the data Sign in
Star measuresDisplay measuresHEDISWhy members leave

Measures · D12 in 2015 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing

Medication Adherence for Hypertension (RAS antagonists)

Drug PlanMedication AdherenceSource: Prescription Drug Events

What it measures
One of the most important ways you can manage your health is by taking your medication as directed. The plan, the doctor, and the member can work together to find ways to help the member take their medication as directed. Percent of plan members with a prescription for a blood pressure medication who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. (“Blood pressure medication” means an ACE (angiotensin converting enzyme) inhibitor, an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.)
How it's calculated
This measure is defined as the percent of Medicare Part D beneficiaries 18 years or older that adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists [angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), or direct renin inhibitor medications]. This percentage is calculated as the number of member-years of enrolled beneficiaries 18 years and older with a proportion of days covered (PDC) at 80 percent or over for RAS antagonist medications during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 18 years or older with at least two fills of either the same medication or medications in the drug class during the measurement period (denominator). The PDC is the percent of days in the measurement period “covered” by prescription claims for the same medication or another in its therapeutic category. Patients are only included in the measure calculation if the first fill of their medication occurs at least 91 days before the end of the enrollment period. The Part D Medication Adherence measure is adapted from the Medication Adherence-Proportion of Days Covered measure that was developed and endorsed by the Pharmacy Quality Alliance (PQA). The PDC Adherence measures are also endorsed by the National Quality Forum (NQF). See the medication list for this measure. The Part D Medication Adherence rate is calculated using the National Drug Code (NDC) list and obsolete NDC date methodology maintained by the PQA. The complete NDC list will be posted along with these technical notes. For the 2015 Star Ratings, NDCs with obsolete dates will be included in the measure calculation if their obsolete dates as reported by PQA are within the period of measurement (measurement year).
Data source
Prescription Drug Event (PDE) data; Medicare Enrollment Database (EDB) File; The data for this measure come from PDE data files submitted by drug plans to Medicare for January 1, 2013-December 31, 2013 by June 30, 2014. Only final action PDE claims are used to calculate the patient safety measures. PDE claims are limited to members who received at least two prescriptions for RAS antagonist medication(s). PDE adjustments made post-reconciliation were not reflected in this measure.
Measurement period
01/01/2013 - 12/31/2013
Better when
Higher
Weight
3 (Intermediate Outcome Measure)
Star assignment
Relative Distribution and Clustering
Case-mix adjusted
—
In improvement measure
Yes
Used in CAI
—
Exclusions
ShowA percentage is not calculated for contracts with 30 or fewer beneficiary member years (in the denominator).
Notes
Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the medication or NDC lists, are excluded from CMS analyses. Also, member-years of enrollment is the adjustment made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the spell level, and inclusion in the measure is determined separately for each spell – i.e., to be included for a given spell, the beneficiary must meet the initial inclusion criteria for the measure during that spell. The measure is weighted based on the total number of member years for each spell in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three month spell, disenrolled for a six month spell, reenrolled for a three month spell, and meets the measure criteria during each enrollment spell , s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12). The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the Medi-Span generic ingredient name. The calculation also adjusts for Part D beneficiaries’ stays in inpatient (IP) settings, hospice enrollments, and stays in skilled nursing facilities (SNFs). The SNF adjustment only applies to PDPs because SNF data are not currently available for MA-PDs. Please see Attachment L: Medication Adherence Measure Calculations for more information about these calculations.

From the 2015 Star Ratings Technical Notes (CMS).

Cut points over time

Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.

How the 2028 cut points are projected

Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.

StarsOrg type2027Projected 2028Move
2★MA-PD8485+1
3★MA-PD8889+1
4★MA-PD9091+1
5★MA-PD9394+1
2★PDP8788+1
3★PDP8990+1
4★PDP9091+1
5★PDP92920

2015 star distribution

Not rated: Plan too new to be measured (154); Plan not required to report measure (13); Not enough data available (10); No data available (4)

Cut point bands

Star yearOrg type1★2★3★4★5★
2027MA-PD< 84 %>= 84 % to < 88 %>= 88 % to < 90 %>= 90 % to < 93 %>= 93 %
2027PDP< 87 %>= 87 % to < 89 %>= 89 % to < 90 %>= 90 % to < 92 %>= 92 %
2026MA-PD< 84 %>= 84 % to < 88 %>= 88 % to < 91 %>= 91 % to < 93 %>= 93 %
2026PDP< 88 %>= 88 % to < 90 %>= 90 % to < 91 %>= 91 % to < 93 %>= 93 %
2025MA-PD< 83 %>= 83 % to < 87 %>= 87 % to < 90 %>= 90 % to < 92 %>= 92 %
2025PDP< 87 %>= 87 % to < 89 %>= 89 % to < 90 %>= 90 % to < 92 %>= 92 %
2024MA-PD< 82 %>= 82 % to < 86 %>= 86 % to < 89 %>= 89 % to < 91 %>= 91 %
2024PDP< 87 %>= 87 % to < 89 %>= 89 % to < 91 %>= 91 % to < 94 %>= 94 %
2023MA-PD< 78 %>= 78 % to < 86 %>= 86 % to < 89 %>= 89 % to < 91 %>= 91 %
2023PDP< 86 %>= 86 % to < 89 %>= 89 % to < 91 %>= 91 % to < 96 %>= 96 %
2022MA-PD< 74 %>= 74 % to < 82 %>= 82 % to < 87 %>= 87 % to < 90 %>= 90 %
2022PDP< 85 %>= 85 % to < 88 %>= 88 % to < 89 %>= 89 % to < 91 %>= 91 %
2021MA-PD< 80 %>= 80 % to < 84 %>= 84 % to < 87 %>= 87 % to < 89 %>= 89 %
2021PDP< 84 %>= 84 % to < 86 %>= 86 % to < 88 %>= 88 % to < 90 %>= 90 %
2020MA-PD< 80%? 80% to < 83%? 83% to < 86%? 86% to < 88%? 88%
2020PDP< 83%? 83% to < 85%? 85% to < 88%? 88% to < 90%? 90%
2019MA-PD< 79%? 79% to < 83%? 83% to < 86%? 86% to < 88%? 88%
2019PDP< 84%? 84% to < 86%? 86% to < 87%? 87% to < 89%? 89%
2018MA-PD< 74%? 74% to < 78%? 78% to < 82%? 82% to < 85%? 85%
2018PDP< 78%? 78% to < 83%? 83% to < 86%? 86% to < 89%? 89%
2017MA-PD< 71%? 71% to < 75%? 75% to < 79%? 79% to < 83%? 83%
2017PDP< 77%? 77% to < 80%? 80% to < 83%? 83% to < 85%? 85%
2016MA-PD< 58%? 58% to < 73%? 73% to < 77%? 77% to < 81%? 81%
2016PDP< 76%? 76% to < 78%? 78% to < 82%? 82% to < 85%? 85%
2015MA-PD< 72%? 72% to < 76%? 76% to < 81%? 81% to < 85%? 85%
2015PDP< 72%? 72% to < 76%? 76% to < 81%? 81% to < 84%? 84%

Lowest-scoring contracts, 2015

ContractParentMembersScoreStarsΔShortfall to 4★Pctile
H9285 ATLANTIS HEALTH PLAN, INC.America's 1st Choice NY Holdings, LLC—621—190%
H0908 WellcareCentene Corporation8,453621—190%
S2505 WINDSOR HEALTH PLAN, INC.WellCare Health Plans, Inc.—681—130%
H5887 MMM HEALTHCARE, INC.InnovaCare Inc.—621—190%
H0901 AETNA HEALTH, INC. (PA)Aetna Inc.—641—171%
H5430 WellCareCentene Corporation—641—171%
H3337 LIBERTY HEALTH ADVANTAGE, INC.Liberty Health Advantage, Inc.—661—151%
H5943 VillageHealthSCAN Group649661—151%
H5969 AlohaCareAlohaCare2,637661—151%
H2773 Quality Health Plans Of New York, Inc.QHP Financial Group, Inc.—661—151%
S7694 Elixir InsuranceRite Aid Corporation—691—122%
H0251 UnitedHealthcareUnitedHealth Group, Inc.76,188671—142%
H0490 Molina Healthcare Of Ohio, Inc.Molina Healthcare, Inc.,—671—142%
H5774 Triple S AdvantageGuidewell Mutual Holding Corporation121,384671—142%
H6972 HEALTHSPRING LIFE & HEALTH INSURANCE COMPANY, INC.CIGNA—671—142%
H8189 WellcareCentene Corporation12,646671—142%
H5640 IEHP HEALTH ACCESSINLAND EMPIRE HEALTH PLAN—671—142%
H4227 VISTA Health Plan Inc.Independence Health Group, Inc.23,267671—142%
H5294 WellcareCentene Corporation16,255671—142%
H4011 MMM HEALTHCARE, LLC.InnovaCare Inc.—671—142%
H8130 Molina Healthcare of FloridaMolina Healthcare, Inc.,—671—142%
H1903 WELLCARE OF LOUISIANA, INC.WellCare Health Plans, Inc.—671—142%
S2874 HumanaHumana Inc.—711—104%
H5698 WINDSOR HEALTH PLAN, INC.WellCare Health Plans, Inc.—681—134%
R9896 CARE IMPROVEMENT PLUS SOUTH CENTRAL INSURANCE CO.UnitedHealth Group, Inc.—681—134%

History

Star yearCodeNameMeasuredWeightSource
2027D09Medication Adherence for Hypertension (RAS antagonists)01/01/2025 – 12/31/20253Prescription Drug Events
2026D09Medication Adherence for Hypertension (RAS antagonists)01/01/2024 – 12/31/20243Prescription Drug Events
2025D09Medication Adherence for Hypertension (RAS antagonists)01/01/2023 – 12/31/20233Prescription Drug Events
2024D09Medication Adherence for Hypertension (RAS antagonists)01/01/2022 – 12/31/20223Prescription Drug Events
2023D09Medication Adherence for Hypertension (RAS antagonists)01/01/2021 – 12/31/20213Prescription Drug Events
2022D09Medication Adherence for Hypertension (RAS antagonists)01/01/2020 – 12/31/20203Prescription Drug Events
2021D11Medication Adherence for Hypertension (RAS antagonists)01/01/2019 – 12/31/20193Prescription Drug Events
2020D11Medication Adherence for Hypertension (RAS antagonists)01/01/2018 – 12/31/20183Prescription Drug Events
2019D11Medication Adherence for Hypertension (RAS antagonists)01/01/2017 – 12/31/20173Prescription Drug Events
2018D12Medication Adherence for Hypertension (RAS antagonists)01/01/2016 – 12/31/20163Prescription Drug Events
2017D13Medication Adherence for Hypertension (RAS antagonists)01/01/2015 - 12/31/20153Prescription Drug Events
2016D13Medication Adherence for Hypertension (RAS antagonists)01/01/2014 - 12/31/20143Prescription Drug Events
2015D12Medication Adherence for Hypertension (RAS antagonists)01/01/2013 - 12/31/20133Prescription Drug Events